This morning regenerative medicine business Admedus Ltd (ASX: AHZ) reported its results for the year ending June 30, 2017. Below is a summary of the results with comparisons to the prior corresponding year.
- Net loss of $12.7m, decrease of 50%
- Revenues of $22.3m, up 58%
- Net operating cash outflow of $12.5m, compared to $21.9m in prior year
- Operating expenses reduced by $8.4m or 25%
- Conducted a capital raising of $17.1m
- Cash on hand of $11.3m
After a strategic review named “Code Red” the company has delivered improved financials on an FY 2016 that delivered cash outflows as high as $21.9 million. The group also highlighted the 30% growth in sales across its Adapt portfolio of regenerative medicine products focused on cardiac repair.
The company also has a profitable general medical equipment business named Infusion, while it is also investing heavily in a business that conducts clinical trials on treatments for a wide variety of common human conditions.
Admedus also forecast that it expects to “approach financial break even in the last quarter of calendar 2018 with the expectation of being profitable for the full calendar year 2019.” The stock is down 30% over the past year and the company will need to deliver a dramatic turnaround to deliver on management’s forecasts. Given its track record of consuming shareholder capital and delivering losses this is a stock I have repeatedly suggested investors avoid. And not for nothing either.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Tom Richardson has no interest in any security mentioned.
You can find Tom on Twitter @tommyr345
The Motley Fool has no interest in any company mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- On a serendipitous day, Tom Richardson is leaving the building – December 17, 2019 11:55am
- Why Aerometrex shares have doubled their IPO price – December 16, 2019 4:32pm
- Why the National Veterinary Care share price is going nuts today – December 16, 2019 3:39pm